BeiGene helped mRNA therapeutics developer Strand Therapeutics raise $52m while the Afterpay-backed AP Ventures led logistics provider Sendle's $35m series C round.

Novo and Orlando Health helped the haemodialysis technology provider increase its overall funding to $350m since it was spun off by IMI.

Harvard-aligned venture capital firm Xfund has reinvested in ImmuneID, which is developing precision immunology therapies based on Harvard University and Johns Hopkins University research.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

MIT mRNA therapeutics spinout Strand has secured series A funding from BeiGene, Redmile Group, Camford Capital, Playground Global and Anri.

Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences, helped the replacement therapy developer close its series B round.

Long-term investor Boston Scientific is paying $295m upfront for the 73% of the ablation technology developer it does not own.

Sanofi Ventures co-led replacement therapy developer Glycomine's latest round, which included Novo, Asahi Kasei Pharma Ventures and Chiesi Ventures.

Alexandria Venture Investments backed precision immunology therapeutics developer ImmuneID in the round, which was led by venture capital firm Alta Partners.

Boston Scientific has acquired all remaining shares in its portfolio company Farapulse, having first invested in the University of Iowa spinout in 2014.